Expertise in
4
conditions

Dr. David A. Parks

Internal Medicine
Novus Health Inc.
3960 Lindell Blvd, 
Saint Louis, MO 
Expertise in
4
conditions
Novus Health Inc.
3960 Lindell Blvd, 
Saint Louis, MO 

Overview

David Parks is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri.

Dr. Parks is highly rated in 4 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 6 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Novus Health Inc.
3960 Lindell Blvd, Saint Louis, MO 63108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Biological
Study Drug: TMB-365
Study Phase: Phase 1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
View 5 Less Clinical Trials

3 Total Publications

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: July 18, 2020
Similar Doctors
Expertise in
28
conditions
Dr. Michael P. Whyte
Internal Medicine
Expertise in
28
conditions
Dr. Michael P. Whyte
Internal Medicine

Office

4921 Parkview Pl Ste 5C, 
Saint Louis, MO 
 (1.2 miles away)
314-454-7775
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Whyte is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Whyte is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Hypophosphatasia (HPP), Juvenile Paget's Disease, Rickets, Osteopetrosis, and Leg or Foot Amputation. Dr. Whyte is currently accepting new patients.

Expertise in
13
conditions
Dr. John C. Morris
Internal Medicine
Expertise in
13
conditions
Dr. John C. Morris
Internal Medicine

Office

4488 Forest Park Ave Ste 160, 
Saint Louis, MO 
 (0.7 miles away)
314-286-1967
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Morris is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Morris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Developmental Dysphasia Familial, Primary Amyloidosis, and Vertebroplasty. Dr. Morris is currently accepting new patients.

Expertise in
11
conditions
Dr. Daniel C. Link
Internal Medicine
Expertise in
11
conditions
Dr. Daniel C. Link
Internal Medicine

Barnes-Jewish Hospital

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (1.2 miles away)
314-454-8304
Languages Spoken:
English

Daniel Link is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Link is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Agranulocytosis, Severe Congenital Neutropenia, Cyclic Neutropenia, and Chronic Familial Neutropenia.

Frequently Asked Questions about Dr. David A. Parks

How do I make an appointment with Dr. David A. Parks?

You can book an appointment with Dr. David A. Parks by calling their office at 314-652-0100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David A. Parks a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David A. Parks is classified as an Advanced expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David A. Parks specialize in?

While Dr. David A. Parks is a Internal Medicine, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dysmorphic Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. David A. Parks participate in research or clinical trials?

Yes. Dr. David A. Parks has published 3 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. David A. Parks's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David A. Parks accept my insurance?

Dr. David A. Parks accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-652-0100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parks's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile